A detailed history of Efg Asset Management (North America) Corp. transactions in Legend Biotech Corp stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 59,078 shares of LEGN stock, worth $2.42 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
59,078
Previous 71,079 16.88%
Holding current value
$2.42 Million
Previous $3.15 Million 8.58%
% of portfolio
0.49%
Previous 0.56%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$43.55 - $59.88 $522,643 - $718,619
-12,001 Reduced 16.88%
59,078 $2.88 Million
Q2 2024

Jul 25, 2024

BUY
$39.5 - $57.22 $71,890 - $104,140
1,820 Added 2.63%
71,079 $3.15 Million
Q1 2024

May 13, 2024

BUY
$55.06 - $69.99 $495,595 - $629,979
9,001 Added 14.94%
69,259 $3.88 Million
Q4 2023

Feb 08, 2024

SELL
$57.25 - $69.74 $676,351 - $823,908
-11,814 Reduced 16.39%
60,258 $3.63 Million
Q3 2023

Nov 02, 2023

SELL
$63.16 - $76.5 $571,029 - $691,636
-9,041 Reduced 11.15%
72,072 $4.84 Million
Q2 2023

Jul 28, 2023

SELL
$46.28 - $75.01 $1.31 Million - $2.12 Million
-28,243 Reduced 25.83%
81,113 $5.6 Million
Q1 2023

Apr 27, 2023

BUY
$43.42 - $57.37 $311,581 - $411,687
7,176 Added 7.02%
109,356 $5.27 Million
Q4 2022

Feb 03, 2023

BUY
$38.8 - $55.46 $428,817 - $612,943
11,052 Added 12.13%
102,180 $5.1 Million
Q3 2022

Oct 28, 2022

SELL
$38.15 - $57.1 $300,622 - $449,948
-7,880 Reduced 7.96%
91,128 $3.72 Million
Q2 2022

Aug 04, 2022

SELL
$33.54 - $55.0 $121,951 - $199,980
-3,636 Reduced 3.54%
99,008 $5.45 Million
Q1 2022

Apr 26, 2022

BUY
$31.02 - $48.18 $773,204 - $1.2 Million
24,926 Added 32.07%
102,644 $3.73 Million
Q4 2021

Feb 18, 2022

BUY
$41.14 - $56.98 $3.2 Million - $4.43 Million
77,718 New
77,718 $3.62 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.85B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.